a Phase II, Randomized, Double‐Blind, Placebo‐Controlled Study of Simtuzumab in Combination With FOLFIRI for the Second‐Line Treatment of Metastatic KRAS Mutant Colorectal Adenocarcinoma
Oncologist - United States
doi 10.1634/theoncologist.2016-0479
Full Text
Open PDFAbstract
Available in full text
Date
February 28, 2017
Authors
Publisher
Alphamed Press